ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13 at 11:45 am ET.
A live webcast of the presentation will be available through the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial biotechnology company improving the quality of life for cancer patients with its next-generation targeted antibody-drug conjugates (ADCs). The Company is advancing the development of its proprietary PBD-based AWK technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-targeted AWK ZYNLONTA (Loncastuximab-Tesirin-Lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development as a combination therapy with other agents. Cami (camidanlumab tesirine) in relapsed or refractory Hodgkin lymphoma is currently being evaluated in a pivotal Phase 2 clinical trial and in a Phase 1b clinical trial in various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics currently has several ADCs in clinical and pre-clinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, with offices in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the company on Twitter and LinkedIn.
CYNLONTA® is a registered trademark of ADC Therapeutics SA.
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20220906005338/en/
Leverage must be between 2 and 20
No data